Glaxo shares ease on 'lethal drug' warning
Friday 04 April 1997
Lamictal, an anti-epilepsy drug launched in Ireland in 1990, has been implicated in recent tests as the cause of a possibly fatal skin condition in children.
Following talks with the Food and Drug Agency in the US, Glaxo revealed yesterday that it had last week issued warnings to doctors of the increased risks and is sending out letters in the UK and the rest of the world where the product is licensed.
Glaxo's shares fell 20.5p at one stage yesterday, but later recovered to end just 6p lower at 1,087p. Analysts were relatively sanguine about the impact of the news on the group, despite the fact that Lamictal is one of the new products identified last month by Glaxo Wellcome chief executive Sir Richard Sykes to take up the running from the best-selling Zantac anti-ulcer drug after key patents expire this year.
One follower said: "This will not have a big effect on earnings or the valuation of the company, but it will have an impact on drug sales."
Sales of Lamictal, market leader in the UK, jumped 64 per cent to pounds 105m last year. Analysts were expecting that figure to grow to around pounds 150m in 1997, rising to a peak of pounds 350m by 2000. The figures compare with pounds 8.34bn for the whole group last year, including pounds 1.93bn for Zantac.
Although Lamictal is not yet registered for paediatric use in the US, the world's biggest drugs market, analysts said the under-16 year old age group was a reasonably significant proportion of the market for the product. It has been licensed for use by children in 25 countries, including the UK from 1994. City projections of sales for the drug are therefore likely to be reined back.
The worries over Lamictal emerged after tests on the use of the drug in children suffering from Lennox-Gastaut syndrome, an acute form of epilepsy which particularly affects children. That showed two out of the 79 children involved developed a serious skin reaction, which led the FDA to suggest the drug results in side-effects for between one in 50 and one in 100 users.
A Glaxo Wellcome spokesman said its own case studies using a wider range of data from around the world showed the incidence to be more like between one in 100 up to one in 300 who developed a reaction.
She admitted, however, that the problem appeared to be worse than in tests conducted before the product was originally licensed, when the incidence was similar to that in adults at one in 1,000 users. Problems can range from a mild skin rash to so-called toxic epidermal necrolysis, a serious skin condition akin to third degree burns. Glaxo said there had been "a handful" of deaths among more than 800,000 people who have used Lamictal since its introduction.
- 1 Autistic teenager beaten up by bullies makes them watch 20-minute video about autism
- 2 Greece debt crisis explained: A history of just how the country landed itself in such a mess
- 3 People all over the world are getting semicolon tattoos to draw attention to mental health
- 4 Greek debt crisis: Yanis Varoufakis's funniest (and most memorable) quotes
- 5 The biggest first date turnoff has been revealed
Greece debt crisis explained: A history of just how the country landed itself in such a mess
Swedish minister gives strongest case yet on why EU should stop turning away asylum seekers
Man dies instantly after shooting firework from top of his head
Isis schoolgirl Amira Abase who fled London to join terrorists in Syria mocks victims of Tunisia massacre
Father faces deportation to Thailand after 27 years in Britain for two 'stupid crimes'
More Britons believe that multiculturalism makes the country worse - not better, says poll
Nathan Collier: Montana man inspired by same-sex marriage ruling requests right to wed two wives
Osborne to cap family benefits at £23,000 – announced ahead of his post-election Budget
Greece crisis: IMF was pushed around by Angela Merkel and Nicholas Sarkozy – and now it is being humiliated
Forget little green men – aliens will look like humans, says Cambridge University evolution expert
Girl, 7, stares down hate preacher at Ohio festival with pro-LGBT rainbow flag gesture
iJobs Money & Business
competitive: SThree: Are you passionate about sales?Do you have a keen interes...
£17000 - £30000 per annum: Recruitment Genius: This is an exciting opportunity...
£15000 - £17000 per annum: Recruitment Genius: This company offers a range of ...
£15000 - £16000 per annum: Recruitment Genius: Customer Service Advisors are r...